Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

Autor: Ocáriz-Díez, M., Cruellas, M., Gascón, M., Lastra, R., Martínez-Lostao, L., Ramírez-Labrada, A., Paño, J.R., Sesma, A., Torres, I., Yubero, A., Pardo, J., Isla, D., Gálvez, E.M.
Přispěvatelé: Bristol-Myers Squibb, Gilead Sciences, Pfizer, European Commission, Gobierno de Aragón, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Fundación Inocente Inocente, Aspanoa, Asociación Carrera de la Mujer Ciudad de Monzón, ARAID Foundation, AstraZeneca, Roche, Merck Sharp & Dohme, Pierre Fabre, Cruellas, Mara [0000-0002-6953-9675], Gascón, Marta [0000-0002-6811-6654], Martínez Lostao, Luis [0000-0003-3043-147X], Ramírez-Labrada, Ariel [0000-0002-3888-7036], Torres-Ramón, Irene [0000-0003-3387-0558], Pardo, Julián [0000-0003-0154-0730], Isla, Dolores [0000-0002-2483-198X], Gálvez Buerba, Eva Mª [0000-0001-6928-5516]
Rok vydání: 2020
Předmět:
Zdroj: Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Digital.CSIC. Repositorio Institucional del CSIC
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
Popis: The advances in molecular biology and the emergence of Next Generation Sequencing (NGS) have revealed that microbiome composition is closely related with health and disease, including cancer. This relationship affects different levels of cancer such as development, progression, and response to treatment including immunotherapy. The efficacy of immune checkpoint inhibitors (ICIs) may be influenced by the concomitant use of antibiotics before, during or shortly after treatment with ICIs. Nevertheless, the linking mechanism between microbiote, host immunity and cancer is not clear and the role of microbiota manipulation and analyses in cancer management has not been clinically validated yet. Regarding the use of microbiome as biomarker to predict ICI efficacy it has been recently shown that the use of biochemical serum markers to monitor intestinal permeability and loss of barrier integrity, like citrulline, could be useful to monitor microbiota changes and predict ICI efficacy. There are still many unknowns about the role of these components, their relationship with the microbiota, with the use of antibiotics and the response to immunotherapy. The next challenge in microbiome research will be to identify individual microbial species that causally affect lung cancer phenotypes and response to ICI and disentangle the underlying mechanisms. Thus, further analyses in patients with lung cancer receiving treatment with ICIs and its correlation with the composition of the microbiota in different organs including the respiratory tract, peripheral blood and intestinal tract could be useful to predict the efficacy of ICIs and its modulation with antibiotic use. JP reported research funding from BMS and Gilead and speaker honoraria from Gilead and Pfizer. EG reported research funding from BMS and Gilead. JP and EG were funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017-83120-C2- 1-R), Fundacion Inocente Inocente, ASPANOA and Carrera de la Mujer de Monzón. JP was supported by ARAID Foundation. DI reported consultation honoraria from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Merck, MSD, Novartis, Pierre Fabre, Pfizer, and Takeda. DI reported speaker honoraria from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, MSD, Novartis, Pierre Fabre, and Pfizer. DI reported research grant from AstraZeneca, BMS, F. Hoffmann-La Roche, MSD, and Pierre Fabre.
Databáze: OpenAIRE
Externí odkaz: